In the September Journal Club, we will be looking at new data from a recent human trial of senolytics at the Mayo Clinic.
Click on the photo to watch the video.
This study is a follow up to their previous human trials targeting IPF. The researchers conducted a study this time to determine if senolytics can remove senescent human cells and how they affect diabetic kidney disease.
Senescent cells, which can release factors that cause inflammation and dysfunction, the senescence-associated secretory phenotype (SASP), accumulate with ageing and at etiological sites in multiple chronic diseases. Senolytics such as Dasatinib + Quercetin (D+Q) selectively eliminates senescent cell by temporarily disabling prosurvival networks which defend them from their own apoptotic environments. In the first clinical trial of senolytics, D + Q improved physical function in patients with idiopathic pulmonary fibrosis (IPF), a fatal senescence-associated disease, but to date, no peer-reviewed study has directly demonstrated that senolytics decrease senescent cells in humans.
Refer to the following:
Hickson, L. J., Prata, L. G. L., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., … & Kellogg, T. A. (2019). Senolytics reduce senescent human cells: A preliminary report of a clinical study of Dasatinib and Quercetin on individuals with diabetic renal disease. EBioMedicine.